HPI Effect in Robotic Urological Surgery on AKI
Effect of Use of Hypotension Prediction System in Prevention of Postoperative Acute Kidney Injury in Robotic-assisted Urologic Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Seoul
-
Seoul, Seoul, South Korea, 07985
- Ewha Womans University Mokdong Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≧ 19
- Patients undergoing robot-assisted urological surgery
Exclusion Criteria:
- Unable to voluntarily give consent
- Unable to use both radial arteries due to such reasons: prior surgery on the radial artery, breast cancer history with axillary LN dissection, AV fistula for renal replacement therapy, or abnormal Allen's test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HPI
Managing intraoperative hemodynamic condition under the HPI guidance
|
The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
|
|
No Intervention: Control
Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute kidney injury
Time Frame: Seven day after the operation
|
Occurrence of acute kidney injury after robotic urological surgery
|
Seven day after the operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depth and duration of hypotension
Time Frame: From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia
|
Depth and duration of hypotension will be assessed by calculating time weighted average (TWA) of hypotension under mean arterial pressure under 65 mmHg during the operation
|
From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia
|
|
Hypotension prediction index
Time Frame: From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia
|
Time weighted average of hypotension prediction index during the operation
|
From applying HPI (hypotension prediction index) monitor to the arterial line to the end of the anesthesia
|
|
Biomarkers
Time Frame: Baseline, immediate postop
|
Biomarkers for early detection of AKI - Cystacin C, KIM-1
|
Baseline, immediate postop
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urologic Neoplasms
- Prostatic Neoplasms
- Urologic Diseases
- Kidney Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- 2023-02-016-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.